Geriatrics Department of Endocrinology and Metabolism, Guangxi Medical University First Affiliated Hospital, Nanning, Guangxi, China.
Guangxi Clinical Research Center for Cardiocerebrovascular Diseases, Guangxi Medical University First Affiliated Hospital, Nanning, Guangxi, China.
BMJ Open. 2022 Jun 6;12(6):e052443. doi: 10.1136/bmjopen-2021-052443.
Mobile health (mHealth)/electronic health (eHealth) have the effect of facilitating weight loss in overweight and obese populations. However, studies have shown varied results and relatively high heterogeneity in the efficacy of mHealth/eHealth interventions. The aim of the paper was to systematically summarise published studies about the weight loss efficacy of mHealth/eHealth.
A comprehensive review of PubMed, Embase and Cochrane Library databases published from inception to 21 March 2021 will be conducted. The selected articles are meta-analyses that integrated the studies, which evaluated efficacy of mHealth/eHealth. Two people will select eligible articles and extract data independently. Any disputes will be resolved by discussion or the arbitration of a third person. The methodological quality of the included meta-analyses will be assessed with AMSTAR V.2 and the quality of evidence will be obtained with Grade of Recommendations Assessment, Development and Evaluation (GRADE). The study selection process will be presented using a flowchart. We will reanalyse each outcome with random effect methods. If possible, we will use funnel plot and Egger's test to evaluate if publication bias existed.
Ethical approval is not required for the study, as we collected data only from available published materials. This umbrella review will also be submitted to a peer-reviewed journal for publication after completion.
CRD42021247006.
移动健康（mHealth）/电子健康（eHealth）在超重和肥胖人群中具有促进减肥的作用。然而，研究表明，mHealth/eHealth 干预措施的效果存在差异，且异质性相对较高。本文旨在系统总结已发表的关于 mHealth/eHealth 减肥效果的研究。
将对从创建到 2021 年 3 月 21 日发表在 PubMed、Embase 和 Cochrane Library 数据库中的研究进行全面综述。选择的文章是整合了评估 mHealth/eHealth 疗效的研究的荟萃分析。两人将独立选择合格的文章并提取数据。任何争议将通过讨论或第三方仲裁解决。将使用 AMSTAR V.2 评估纳入荟萃分析的方法学质量，并使用推荐评估、制定和评估（GRADE）等级获得证据质量。将使用流程图呈现研究选择过程。我们将使用随机效应方法重新分析每个结果。如果可能，我们将使用漏斗图和 Egger 检验来评估是否存在发表偏倚。
该研究不需要伦理批准，因为我们仅从可用的已发表材料中收集数据。完成后，本综述也将提交给同行评议的期刊发表。
PROSPERO 注册号：CRD42021247006。
